15 October 2018 - Deborah Wilkes
Archived
Bristol-Myers Squibb (BMS) says "no decisions" have been made about the future of its French consumer healthcare business UPSA. The company was responding to media reports that Germany's Stada Arzneimittel and three private-equity firms had made offers for the business.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.